Innovate UK

Hexis Lab is a technology company working at the forefront of raw material innovation. Hexis Lab produce ground-breaking ethnically targeted skincare products to protect and repair sun-damaged skin and improve life well-being. The company's discovery platform utilizes big data cloud computing approaches and in-silico computer modelling to screen a huge database of natural plant derived compounds for activity against our selected cellular targets.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

aTen Therapeutics is a biotechnology company focused on developing innovative therapeutic antibodies aimed at treating major diseases, particularly cancer. The company's unique approaches target a fundamental control pathway associated with various diseases, enabling the development of treatments that can significantly improve patient outcomes. aTen Therapeutics' antibodies are designed to inhibit cancer cell growth, invasion, and metastasis across multiple tumor models. By combining these antibodies with anti-cancer agents, the company seeks to enhance the efficacy of cancer treatments and provide healthcare professionals with effective tools to improve the lives of cancer patients while protecting against the progression of metastases. The management team possesses extensive experience in the biopharmaceutical industry, emphasizing the company's commitment to advancing medical science and patient care.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.

Dyman Advanced Materials specializes in the development of a patented technology aimed at enhancing the manufacturing process of synthetic diamonds. This innovative approach seeks to improve the efficiency of the traditional high-pressure and high-temperature method used in diamond synthesis, resulting in reduced production costs. By providing a more economical production method, Dyman's technology serves both the industrial and gemstone market sectors, facilitating the broader availability of high-quality synthetic diamonds.

Vector Homes creates a new method for constructing homes and choosing the materials to use. Vector Homes recycles the materials and enhance them with nanotechnologies to create unique properties for superior construction materials.

Neumind is a developer of technological solutions to help people living with neurological conditions and injuries. The company's app Alfred offers both practical and therapeutic support to individuals, as well as their formal and informal caregivers. It also helps individuals live a more functional and independent life and supports all their caregivers to help them achieve this. Alfred uses the full extent of smartphone technology to support key cognitive functions, stimulate neural pathways and help establish behaviours and strategies that are rooted in neurorehabilitation and cognitive behavioural science. Neumind was founded in 2019 and is headquartered in Great Shelford, Cambridge.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.

Puraffinity was incorporated in 2015 and is headquartered in London. The company specialises in the design of advanced materials, and has developed a bio-based novel adsorbent capable of removing highly challenging pollutants from contaminated water and wastewater. The technology utilises advanced supramolecular chemistry methods to functionalise bio-based materials designed to bind target chemicals. The company is at the forefront of developing solutions for overcoming imminent water quality challenges, whilst sustainable and positive environmental impact lies at the heart of the company’s ethos.

Dyneval specializes in portable technology for cattle semen analysis, focusing on the precise measurement of semen quality. Its innovative technology assesses semen motility under quasi-in-vivo conditions, providing valuable insights into spermatozoa behavior. By utilizing dynescan data, Dyneval aids in informing breeding plans and confirming semen quality throughout the supply chain. This approach not only enhances livestock production but also contributes to improved food security and reduced methane emissions, allowing farmers to address issues related to poor conception rates effectively.

Ionoptika is the provider of high-performance ion beam technologies for surface analysis and nanofabrication applications, and are the experts in cluster ion beams for secondary ion mass spectrometry (SIMS).

We are a startup company based in the Unit DX incubator in Bristol UK, developing our proprietary graphene-based nanomaterials with many advanced properties.

Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.

CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.

Aramune Technologies is developing natural, plant derived feed materials which can be mixed with standard animal feeds to replace antimicrobial agents and promote growth.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

Iceni Labs is an innovation commercialisation enterprise, with integrated research, development, test and manufacturing capability. Inter-disciplinary by nature, we combine commercial expertise with academic excellence, across the Defence and Security, Energy, Health and Consumer sectors. Our professional networks bridge artificial intelligence, automated creativity, electronics, energy, materials, nanotechnology and software. We invent and innovate in-house, foster high-potential technologies, and aggregate capabilities globally, to produce innovative, disruptive products that deliver more than the sum of their parts. By providing technical, executive, commercial and capital support, our Innovation-Exploitation Programme enhances value proposition and reduces risk exposure, while developing creativity, flexibility and robustness. Our goal is for our ‘wrap around’ idea to patent to product approach to become recognised globally as a catalyst for successful innovation. We are bridging the challenging gap between ‘thinking’ and ‘doing’.

Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel. This diverts the blood away from the aneurysm, allowing it to heal.

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Developer of a seed enhancement technology designed to reduce seed losses that make it hard for forestry organizations to meet government goals on tree planting. The company specializes in developing novel products that will significantly improve yield results in both the Forestry and the Agriculture sector, and technology coats seeds to absorb and retain moisture, enabling growers to increase seed germination in dry conditions.

BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.

DIOSyn Vax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines) is new technology that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.

Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of a silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have sustained injuries due to trauma or cancer surgery. This innovative approach eliminates the risks associated with traditional autograft procedures, which are currently considered the gold standard for such repairs. By providing healthcare professionals with a new treatment option, Newrotex aims to enhance patient outcomes and reduce the morbidity associated with conventional nerve repair methods. The intellectual property for this device has been granted, underscoring its potential impact in the medical field.

Kuano Ltd provides quantum and AI solutions for molecular designs. It designs inhibitors to combine quantum simulation and machine learning approaches to create effective inhibitors based on the mechanisms of the target enzyme. It designs and selects modules in various sectors, including pharma, crop protection, and industrial chemistry. The company was incorporated in 2020 and is based in London, United Kingdom.

Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Our co-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. The team has grown to contain commercial expertise that encompasses individuals with a unicon exit in their CV's, as well as multiple startup experience between them. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients.

Evince Technology Ltd develops diamond-based semiconductor devices that reduce carbon dioxide emissions. It offers diamond power semiconductor devices, including diodes, electron field emission triodes, and directional field emission transistors that connect power electronic systems to a mains electricity grid. The company’s products are used to improve the performance wind turbines and fuel cells and reduce the energy requirement of motors. The company was founded in 2004 and is based in Durham, United Kingdom.

Evince Technology Ltd develops diamond-based semiconductor devices that reduce carbon dioxide emissions. It offers diamond power semiconductor devices, including diodes, electron field emission triodes, and directional field emission transistors that connect power electronic systems to a mains electricity grid. The company’s products are used to improve the performance wind turbines and fuel cells and reduce the energy requirement of motors. The company was founded in 2004 and is based in Durham, United Kingdom.

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of a silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have sustained injuries due to trauma or cancer surgery. This innovative approach eliminates the risks associated with traditional autograft procedures, which are currently considered the gold standard for such repairs. By providing healthcare professionals with a new treatment option, Newrotex aims to enhance patient outcomes and reduce the morbidity associated with conventional nerve repair methods. The intellectual property for this device has been granted, underscoring its potential impact in the medical field.

Iceni Labs is an innovation commercialisation enterprise, with integrated research, development, test and manufacturing capability. Inter-disciplinary by nature, we combine commercial expertise with academic excellence, across the Defence and Security, Energy, Health and Consumer sectors. Our professional networks bridge artificial intelligence, automated creativity, electronics, energy, materials, nanotechnology and software. We invent and innovate in-house, foster high-potential technologies, and aggregate capabilities globally, to produce innovative, disruptive products that deliver more than the sum of their parts. By providing technical, executive, commercial and capital support, our Innovation-Exploitation Programme enhances value proposition and reduces risk exposure, while developing creativity, flexibility and robustness. Our goal is for our ‘wrap around’ idea to patent to product approach to become recognised globally as a catalyst for successful innovation. We are bridging the challenging gap between ‘thinking’ and ‘doing’.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.

Dyman Advanced Materials specializes in the development of a patented technology aimed at enhancing the manufacturing process of synthetic diamonds. This innovative approach seeks to improve the efficiency of the traditional high-pressure and high-temperature method used in diamond synthesis, resulting in reduced production costs. By providing a more economical production method, Dyman's technology serves both the industrial and gemstone market sectors, facilitating the broader availability of high-quality synthetic diamonds.

CageCapture creates, develops and supplies novel advanced materials to address some of the most pressing indoor air pollution problems facing modern society.

Naturbeads, a company working to manufacture a replacement ato the ocean-polluting microbeads that, despite initial bans in “rinse-off” cosmetics, are found in many personal and home care products and paints. Naturbeads manufacture a biodegradable alternative to plastic microbeads that could reduce micro plastic pollution in the oceans. The technology to create the cellulose microbeads was developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017

Albotherm specializes in developing and manufacturing innovative passive cooling polymer coatings aimed at addressing climate change and its effects. The company's core technology is a smart transitioning coating that regulates surface temperatures without requiring any energy input. This coating reversibly changes from clear to white when temperatures exceed a specified trigger point, effectively reflecting unwanted light to mitigate overheating. This unique capability enables a range of industries to enhance thermal management in their structures and surfaces, contributing to energy efficiency and climate resilience.

Lunac Therapeutics is a UK-based drug discovery company.

We are a startup company based in the Unit DX incubator in Bristol UK, developing our proprietary graphene-based nanomaterials with many advanced properties.

Cognetivity Neurosciences Ltd. is a healthcare company based in Vancouver, Canada, that specializes in medical technology focused on cognitive assessment. Established in 2011, the company has developed an integrated cognitive testing platform designed for use in both medical and commercial settings. This platform utilizes artificial intelligence to facilitate the early detection of cognitive impairment, dementia, and Alzheimer's disease. By enabling earlier diagnosis, Cognetivity aims to improve patient outcomes and support better management of cognitive health.

high expertise in the designing and testing of self-assembling peptides providing different benefits when culturing adherent cells in vitro.

Naturbeads, a company working to manufacture a replacement ato the ocean-polluting microbeads that, despite initial bans in “rinse-off” cosmetics, are found in many personal and home care products and paints. Naturbeads manufacture a biodegradable alternative to plastic microbeads that could reduce micro plastic pollution in the oceans. The technology to create the cellulose microbeads was developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017

Iceni Labs is an innovation commercialisation enterprise, with integrated research, development, test and manufacturing capability. Inter-disciplinary by nature, we combine commercial expertise with academic excellence, across the Defence and Security, Energy, Health and Consumer sectors. Our professional networks bridge artificial intelligence, automated creativity, electronics, energy, materials, nanotechnology and software. We invent and innovate in-house, foster high-potential technologies, and aggregate capabilities globally, to produce innovative, disruptive products that deliver more than the sum of their parts. By providing technical, executive, commercial and capital support, our Innovation-Exploitation Programme enhances value proposition and reduces risk exposure, while developing creativity, flexibility and robustness. Our goal is for our ‘wrap around’ idea to patent to product approach to become recognised globally as a catalyst for successful innovation. We are bridging the challenging gap between ‘thinking’ and ‘doing’.

Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Bionema is a leading biopesticide product testing and technology development company, specialising in chemical-free, organic crop protection. Research is focused on the development of natural products to protect crops from insect damage, reducing the use of synthetic pesticides, enhancing food security and increasing crop yields. Bionema supplies specialist bio-control products to the horticulture, turf and amenity and forestry sectors, providing training aimed at increasing the product efficacy.

Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons or wi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice. The company was founded in 2015 and is headquartered in Oxford, England.

Neuronostics Ltd is a spin-out from the University of Exeter in the UK, dedicated to developing and commercializing an innovative technology for assessing seizure susceptibility, known as BioEP. The company focuses on diagnosing and prognosing neurological conditions, particularly epilepsy. Its platform utilizes a patented method to calculate a seizure risk score based on routine electroencephalogram (EEG) recordings. This approach aims to enhance early diagnosis and prognosis of epilepsy, thereby enabling healthcare professionals to improve patient quality of life through more informed clinical decisions.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Irresistible Materials Ltd, a materials technology company, develops and commercializes fullerene based photo-resist technology. It offers fullerene materials and processes for application in lithography, including EUV resists, spin-on-carbon, and e-beam resists. The company was incorporated in 2009 and is based in Swansea, United Kingdom.

BioSystems Technology engages in the development of alternative research models. BioSystems Technology was founded by an infectious disease research fellow and a Professor of Molecular Pathogenicity based at the University of Exeter.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal. We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas. This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide. Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.

CN Bio Innovations Ltd, based in Cambridge, United Kingdom, specializes in developing Organ-on-Chip devices aimed at enhancing preclinical drug testing for pharmaceutical and biotechnology companies. The company creates microphysiological systems and consumables that enable consumer goods and chemical firms to assess the toxicity and safety of novel compounds using in vitro studies across various biological processes, including oncology, infectious diseases, metabolism, and inflammation. Formerly known as Zyoxel Ltd, CN Bio is recognized for its proprietary LiverChip® platform, which features a full viral lifecycle model of hepatitis B, called Quantum-B®. This model is utilized in drug discovery and research partnerships with leading industry players. Collaborating with academic experts in bio-engineering and supported by grants from organizations such as the United States Defence Advanced Research Projects Agency and the UK Technology Strategy Board, CN Bio is committed to advancing next-generation organ-on-chip technologies to facilitate the development of innovative therapies that could improve global health outcomes.

Xerion Healthcare Limited is a UK-based company focused on developing and commercializing nanoparticle treatments to enhance the effectiveness of cancer therapies, specifically targeting head, neck, and pancreatic tumors. Founded in 2015, the company utilizes titanium dioxide nanoparticles, a non-toxic semiconductor material, which are injected into tumors prior to standard radiotherapy. This innovative approach amplifies the dose of free radicals produced by X-rays, thereby improving the treatment's efficacy while minimizing potential side effects. By integrating this nanomedicine technology into conventional radiotherapy, Xerion Healthcare aims to provide more effective solutions for patients with challenging cancer types.

CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.

Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.

Activirosomes specializes in the development of innovative vaccines and virotherapies aimed at treating viral infections. Utilizing a unique active virosome technology, the company creates multivalent vaccines that target various diseases, including cancer, avian viruses, and Zika virus. Activirosomes focuses on ensuring that its products are not only effective but also safe and affordable, thereby addressing critical healthcare needs in the field of infectious diseases and oncology.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers specialized cell analysis systems that facilitate the discovery of new cell strains and molecules, aiding scientists in screening for and isolating rare biological variants. Their products serve various applications, including research, therapeutic development, bioproduction, and diagnostics. By providing collaborative research and development services, Sphere Fluidics aims to help clients enhance efficiency, reduce costs, and accelerate advancements in biological and biopharmaceutical discovery.

Plasticell is a biotechnology company focused on developing innovative therapeutics through advanced cell culture and drug discovery platforms. The company specializes in elucidating the biochemical mechanisms that regulate the proliferation and differentiation of stem cells, which are essential for tissue development and repair. By testing a wide range of cell culture variables, Plasticell aims to establish optimal laboratory protocols for various applications in cell biology, gene transduction, protein production, and drug screening. This approach enables researchers to create novel small molecule drugs that promote regenerative medicine and improve therapeutic outcomes.

Smart Separations is a limited company based in London UK that has patented an innovative microfiltration technology to produce ceramic filters with self-assembled controllable pores of uniform size in the range between <1 and 50µm. This tight pore size control and range availability will revolutionise the field of MF with a cost-effective product. It aims to be the world’s leader in MF and particle separations technology – filling the void gap that exists in the market nowadays.

N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need . N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. The company offers a range of products, including induced pluripotent stem cells, primary human and multispecies cells, and a comprehensive cell culture and analysis package. Stemnovate's project, "Liver on chip," focuses on liver toxicity testing and incorporates advanced techniques in cellular reprogramming and organ-on-chip technology. The company also provides services such as cell reprogramming, differentiation, and application development. Its clientele includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions, enabling researchers to overcome challenges associated with traditional mammalian cell lines in drug discovery.

LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF)..

Nandi Proteins Limited is a technology-driven company based in Edinburgh, United Kingdom, focused on enhancing the functional properties of proteins in food manufacturing and nutrition. Established in 2000 and spun out of Heriot Watt University in 2001, the company specializes in patented processes that improve common proteins such as whey, egg, and soy. Nandi Proteins aims to be a leader in denatured protein technology, facilitating growth through direct trading of value-added proteins and strategic licensing agreements with industry partners. Its innovative approach employs a combination of heat, time, and temperature control to modify proteins, enabling food and beverage manufacturers to achieve desirable characteristics and health benefits while efficiently extracting valuable components like enzymes.

Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal. We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas. This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide. Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.

DynamX Medical specializes in the development of a cost-effective and reliable precancer screening system designed for rapid tissue biopsy analysis. This innovative technology enables point-of-care operation, allowing nurses to efficiently conduct screenings in various clinical settings. The company's focus on creating accessible diagnostic tools aims to enhance the identification of healthy and benign tissue specimens, ultimately improving patient care and outcomes. Established in London, United Kingdom, DynamX Medical has positioned itself at the forefront of advancements in medical diagnostics since its inception.

Sarissa Biomedical, Ltd. specializes in the development and production of advanced biosensors aimed at measuring neuroactive chemicals in both in vitro and in vivo environments for research and clinical diagnostics. Founded in 2002 and based in Coventry, United Kingdom, the company offers a range of minimally invasive microelectrode electrochemical sensors that provide high sensitivity and accuracy for detecting purines and other neurochemicals. These sensors serve as important indicators of neurological activity and disorders. Sarissa Biomedical markets its products in various regions, including the United Kingdom, the United States, Canada, and Japan, contributing to advancements in the understanding and diagnosis of neurological conditions.

G2O is a UK-based graphene innovation and application company whose patented technology is aimed at tackling the world’s water shortage.

Tecrea Ltd is involved in basic research that results in transformative technologies for biomedicine. We focus on creative ways to use nanotechnology to improve cell delivery of reagents and drugs. We view cell delivery as a central problem in biological research and biomedicine, and improved delivery strategies can enable better application of many reagents and drugs. By improving delivery, Tecrea Ltd enables scientists to bring forward modern molecular medicines to the clinic.

MICAs novel patented technology utilises magnetic nanoparticles to control cell behaviour inside and outside the body using custom designed and built magnetic arrays. Using this technology we have established a novel dynamic drug screening assay, DYNASCREEN. Further stem cell therapy applications have been explored with ambitions of clinical adoption for the treatment of bone and cartilage injuries. MICA scientists are experienced in functionalising magnetic nanoparticles with any antibody, peptide or small molecule to suit a range of applications.

Locate Bio Limited is a regenerative medicine company specializing in innovative solutions for tissue repair. The company has developed a platform utilizing Targeted, Orchestrated Signaling technology, which focuses therapeutic signals at the site of tissue injuries. This approach enhances the effectiveness of cell therapies and facilitates localized repair by providing a supportive structure for tissue regeneration. Locate Bio’s products are applicable across various clinical fields, including orthopedics, cardiology, neurology, dentistry, and reconstructive surgery. The company's offerings include thermally activated and injectable scaffolds that solidify within the body, enabling advanced pharmaceutical delivery and supporting tissue growth. Established in 2001 and based in Nottingham, United Kingdom, Locate Bio aims to address significant unmet clinical needs, primarily assisting surgeons in improving the quality of life for patients with challenging spinal conditions.

OxSonics Limited develops and commercializes SonoTran, an oncological drug delivery platform and injectable sono-sensitive particles. Its SonoTran drug delivery platform delivers drugs throughout tumours, including to the areas that lie furthest from blood vessels. The company also develops a pipeline of therapies for the treatment of solid tumours, mCRC, and pancreatic ductal adenocarcinoma. OxSonics Limited was founded in 2013 and is based in Oxford, United Kingdom.

Cella Energy Limited is an advanced materials and technologies company based in Didcot, United Kingdom, with additional facilities in Florida. Founded in 2011, the company specializes in developing and producing hydrogen storage materials that can store up to one liter of hydrogen per gram and facilitate transportation at room temperature. Cella Energy's product offerings include various production systems such as smaller scale tray type and industrial scale freeze drying facilities, flowable pellets, static and cartridge systems, and flowing pellet systems. The company caters to a diverse range of applications, including portable power, military power solutions for unmanned systems, and radiation shielding materials designed to protect space satellites from harmful radiation.

Cella Energy Limited is an advanced materials and technologies company based in Didcot, United Kingdom, with additional facilities in Florida. Founded in 2011, the company specializes in developing and producing hydrogen storage materials that can store up to one liter of hydrogen per gram and facilitate transportation at room temperature. Cella Energy's product offerings include various production systems such as smaller scale tray type and industrial scale freeze drying facilities, flowable pellets, static and cartridge systems, and flowing pellet systems. The company caters to a diverse range of applications, including portable power, military power solutions for unmanned systems, and radiation shielding materials designed to protect space satellites from harmful radiation.